2020, Number 06
<< Back Next >>
Ginecol Obstet Mex 2020; 88 (06)
Involvement of TNF-alpha in the polycystic ovary syndrome
Garza-Garza MA, Delgadillo-Guzmán D
Language: Spanish
References: 34
Page: 385-393
PDF size: 314.81 Kb.
ABSTRACT
Background: Polycystic ovary syndrome (PCOS) is a pathology present in 6 to
14% of women. However, in clinical practice it is underdiagnosed, which implies a
presence of complications of the pathology that includes obesity, insulin resistance,
metabolic alterations and infertility. The pathophysiology is not well defined, and
the association of a chronic metabolic and inflammatory process is currently being
considered, where inflammatory cytokines can present alterations both in their effect
and in their signaling.
Objective: To present the results of an updated systematic review of the involvement
of TNF-alpha in polycystic ovary syndrome.
Methodology: Narrative revision of articles indexed in Pub Med-NCBI, Web of
Science, Google Scholar and Scopus, published in English or Spanish between 2014
and 2018 that included the concepts and association of polycystic ovary syndrome
and tumor necrosis factor alpha in the title and abstract.
Results: 43 articles were identified; after eliminating the duplicates, 29 remained and,
in the end, the synthesis was carried out with 11 articles. The publications came from
different countries: 54% of the studies were carried out in Chile, the United States and
Iran, proportionally; the rest of the studies were carried out in Russia, China, Korea,
Egypt and Pakistan.
Conclusions: TNF-alpha is a cytokine associated with different systems that is
involved in polycystic ovary syndrome.
REFERENCES
Evans TN, Riley GM. Polycystic ovarian disease (Stein- Leventhal syndrome); etiology and rationale for surgical treatment. Obstet Gynecol 1958; 12 (2): 168-79.
Dumesic DA, et al. Scientific statement on the diagnostic criteria, epidemiology, pathophysiology, and molecular genetics of polycystic ovary syndrome. Endocr Rev. 2015;36 (5): 487-525. https://doi.org/10.1210/er.2015-1018
Ehrmann DA. Polycystic ovary syndrome. N Engl J Med. 2005; 352 (12): 1223-36. doi: 10.1056/NEJMra041536.
Moran C, et al. Prevalence of polycystic ovary syndrome and related disorders in mexican women. Gynecol Obstet Invest. 2010; 69 (4): 274-80. https://doi. org/10.1159/000277640
Cadagan D, et al. Thecal cell sensitivity to luteinizing hormone and insulin in polycystic ovarian syndrome. Reprod Biol. 2016; 16 (1): 53-60. doi: 10.1016/j.repbio. 2015.12.006
Teede HJ, et al. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Clin Endocrinol (Oxf) 2018; 89 (3): 251-68. doi: 10.1111/cen.13795
Rotterdam EA, et al. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril. 2004; 81 (1): 19-25. doi: 10.1016/j.fertnstert.2003.10.004
Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev 1997; 18 (6): 774-800. doi: 10.1210/edrv.18.6.0318
El Hayek S, et al. Polycystic ovarian syndrome: An updated overview. Front Physiol. 2016; 7: 124. doi: 10.3389/ fphys.2016.00124.
Rosenfield RL. The diagnosis of polycystic ovary syndrome in adolescents. Pediatrics 2015; 136 (6): 1154-65. doi: 10.1542/peds.2015-1430.
Rosenfield RL. The polycystic ovary morphology-polycystic ovary syndrome spectrum. J Pediatr Adolesc Gynecol. 2015; 28 (6): 412-9. doi:10.1016/j.jpag.2014.07.016.
Goodman NF, et al. Guide to the best practices in the evaluation and treatment of polycystic ovary syndrome. Part 1. Endocr Pract. 2015; 21 (11): 1291-300. doi: 10.4158/ EP15748.DSC.
Kelly CC, et al. Low grade chronic inflammation in women with polycystic ovarian syndrome. J Clin Endocrinol Metab 2001; 86 (6): 2453-5. doi: 10.1210/jcem.86.6.7580.
Ojeda-Ojeda M, et al. Mediators of low-grade chronic inflammation in polycystic ovary syndrome (PCOS). Curr Pharm Des. 2013; 19 (32): 5775-91. doi: 10.2174/1381612811319320012.
Spaczynski RZ, et al. Tumor necrosis factor-alpha stimulates proliferation of rat ovarian theca-interstitial cells. Biol Reprod. 1999; 61 (4): 993-8. doi: 10.1095/biolreprod61.4.993.
Hotamisligil GS, et al. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 1993; 259 (5091): 87-91. doi: 10.1126/ science.7678183.
Moller DE. Potential role of TNF-alpha in the pathogenesis of insulin resistance and type 2 diabetes. Trends Endocrinol Metab. 2000; 11 (6): 212-7. doi: 10.1016/ s1043-2760(00)00272-1
Alge JL, et al. Biomarkers of AKI: a review of mechanistic relevance and potential therapeutic implications. CJN 2014. 12191213. https://doi.org/10.2215/CJN.12191213
Kluge MA, et al. Mitochondria and endothelial function. Circ Res. 2013; 112 (8): 1171-88. doi: 10.1161/CIRCRESAHA. 111.300233
Incalza MA, et al. Oxidative stress and reactive oxygen species in endothelial dysfunction associated with cardiovascular and metabolic diseases. Vascul Pharmacol. 2018; 100: 1-19. doi: 10.1016/j.vph.2017.05.005
Keane KN, et al. Molecular events linking oxidative stress and inflammation to insulin resistance and beta-cell dysfunction. Oxid Med Cell Longev. 2015. https://doi. org/10.1155/2015/181643
Thathapudi S, et al. Tumor necrosis factor-alpha and polycystic ovarian syndrome: a clinical, biochemical, and molecular genetic study. Genet Test Mol Biomarkers 2014; 18 (9): 605-9. doi: 10.1089/gtmb.2014.0151
Ihsan I, et al. Tumor necrosis factor-alpha and polycystic ovarian syndrome: a clinical, biochemical, and molecular genetic study. Genet Test Mol Biomarkers. 2014 Sep;18(9):605-9. doi: 10.1089/gtmb.2014.0151
Ihsan I, et al. Significance of TNF-Alpha and Insulin Resistance in Women with Polycystic Ovarian Syndrome. PJMHS 2018; 12 (2): 459-63.
Pawelczak M, et al. Evaluation of the pro-inflammatory cytokine tumor necrosis factor-alpha in adolescents with polycystic ovary syndrome. J Pediatr Adolesc Gynecol. 2014; 27 (6): 356-9. doi: 10.1016/j.jpag.2014.01.104
Artimani T, et al. Evaluation of pro-oxidant-antioxidant balance (PAB) and its association with inflammatory cytokines in polycystic ovary syndrome (PCOS). Gynecol Endocrinol. 2018; 34 (2): 148-52. doi: 10.1080/09513590.2017.1371691
Yang Y, et al. Is interleukin-18 associated with polycystic ovary syndrome? Reproductive Biology and Endocrinology 2011; 9: 7-7. doi: 10.1186/1477-7827-9-7
Younis A, et al. Serum tumor necrosis factor-alpha, interleukin- 6, monocyte chemotactic protein-1 and paraoxonase- 1 profiles in women with endometriosis, PCOS, or unexplained infertility. J Assist Reprod Genet. 2014; 31 (11): 1445-51. doi: 10.1007/s10815-014-0237-9.
Seyam E, et al. Tumor necrosis factor alpha versus LH and androstendione as a reliable predictor of spontaneous ovulation after laparoscopic ovarian drilling for women with clomiphene citrate resistance polycystic ovarian disease. Eur J Obstet Gynecol Reprod Biol. 2018; 222: 126-33. doi: 10.1016/j.ejogrb.2018.01.011.
Artimani T, et al. Follicular fluid concentrations of interleukin- 6, Interleukin-8, TNF-[alpha] and interleukin 10 in polycystic ovarian syndrome women. Fertil and Steril. 2015; 9: 75. doi: 10.22074/ijfs.2015.4428
Zhang T, et al. Detection of dendritic cells and related cytokines in follicular fluid of patients with polycystic ovary syndrome. Am J Reprod Immunol. 2017; 78 (3). doi: 10.1111/aji.12717
Orostica L, et al. Proinflammatory environment and role of TNF-alpha in endometrial function of obese women having polycystic ovarian syndrome. Int J Obes (Lond). 2016; 40 (11): 1715-22. doi: 10.1038/ijo.2016.154
Chistyakova GN et al. Immunological and hemostasiological disorders in women with ovarian hyperstimulation syndrome. Gynecol Endocrinol. 2014 Oct;30 Suppl 1:39-42. doi: 10.3109/09513590.2014.945787.
Lee JY et al. Expression of the genes for peroxisome proliferator-activated receptor-γ, cyclooxygenase-2, and proinflammatory cytokines in granulosa cells from women with polycystic ovary syndrome. Clin Exp Reprod Med. 2017 Sep;44(3):146-151. doi: 10.5653/ cerm.2017.44.3.146.